Igualtuss

Description

Igualtuss is a pharmaceutical formulation indicated for the management of cough. The active ingredient is a combination of antitussive and expectorant agents, designed to alleviate symptoms associated with respiratory conditions. The product is available in a liquid dosage form, characterized by a clear to slightly opalescent appearance. The formulation is designed to provide effective relief while maintaining a favorable safety profile. Specific details regarding the molecular weight and chemical formula are proprietary and not disclosed.

Uses and Indications

This drug is indicated for the temporary relief of cough associated with minor throat and bronchial irritations, which may occur due to the common cold or inhaled irritants. It also aids in loosening phlegm (mucus) and thinning bronchial secretions, thereby making coughs more productive. Additionally, this drug provides temporary relief from nasal congestion resulting from the common cold.

Limitations of Use: This medication is intended for symptomatic relief and does not address the underlying causes of cough or nasal congestion.

Dosage and Administration

Adults and children over 12 years of age are advised to take 1 teaspoonful (5 mL) every 6 to 8 hours as needed. The total number of doses should not exceed 4 doses within a 24-hour period.

For children aged 6 to under 12 years, the recommended dosage is 1/2 teaspoonful (2.5 mL) every 6 to 8 hours, ensuring that the total does not exceed 4 doses in a 24-hour period.

It is important to note that for children under 6 years of age, consultation with a healthcare professional is required prior to use.

Contraindications

There are no contraindications associated with the use of this product. It is not classified as a controlled substance, and there are no known risks of abuse, misuse, or dependence. Additionally, there are no specific instructions indicating that the product should not be taken or used under any circumstances.

Warnings and Precautions

Patients should not use this product if they are currently taking a prescription Monoamine Oxidase Inhibitor (MAOI), which includes certain medications for depression, psychiatric or emotional conditions, or Parkinson's disease. Additionally, use is contraindicated for a period of two weeks following the discontinuation of an MAOI. If there is uncertainty regarding the presence of an MAOI in any current prescription, patients are advised to consult their healthcare provider or pharmacist prior to use.

General precautions should be observed. Patients should seek medical advice before using this product if they have any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, difficulty urinating due to prostate gland enlargement, a cough with excessive phlegm, or a persistent or chronic cough associated with smoking, asthma, chronic bronchitis, or emphysema. Furthermore, it is important to consult a healthcare professional if the patient is taking sedatives, tranquilizers, or any medications for depression, including MAOIs.

Patients are instructed to discontinue use and contact their healthcare provider if they experience nervousness, dizziness, or sleeplessness. Additionally, if a cough persists for more than seven days, recurs, or is accompanied by fever, rash, or a headache that lasts, these may indicate a serious condition requiring medical evaluation.

In the event of an accidental overdose, immediate medical assistance should be sought by contacting a healthcare provider or a Poison Control Center.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. Serious warnings include the contraindication of use in individuals currently taking a prescription Monoamine Oxidase Inhibitor (MAOI) or within two weeks of discontinuing such treatment, as this may lead to significant interactions.

Before initiating therapy, patients with pre-existing conditions should consult a healthcare professional if they have heart disease, high blood pressure, thyroid disease, diabetes, difficulty urinating due to prostate gland enlargement, or a cough that produces excessive phlegm. Additionally, those with a persistent or chronic cough, such as that associated with smoking, asthma, chronic bronchitis, or emphysema, should seek medical advice prior to use.

Patients are advised to discontinue use and consult a healthcare provider if they experience nervousness, dizziness, or sleeplessness. Furthermore, if a cough persists for more than seven days, recurs, or is accompanied by fever, rash, or headache, these symptoms may indicate a serious underlying condition that requires medical evaluation.

Drug Interactions

The concomitant use of this medication with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated. Patients should not use this medication if they are currently taking a prescription MAOI, which includes certain drugs prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. Additionally, it is advised to avoid this medication for a period of two weeks following the discontinuation of an MAOI.

Furthermore, patients are encouraged to consult a healthcare professional prior to using this medication if they are concurrently taking sedatives, tranquilizers, or any other drugs indicated for depression, including MAOIs. This precaution is essential to mitigate potential pharmacodynamic interactions that may enhance sedative effects or lead to adverse reactions.

Packaging & NDC

Below are the non-prescription pack sizes of Igualtuss (dextromethorphan hbr, guaifenesin, phenylephrine hcl). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may take 1/2 teaspoonful (2.5 mL) every 6-8 hours. For children under 6 years of age, it is advised to consult a doctor prior to use.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as they may have altered pharmacokinetics and pharmacodynamics. Close monitoring is recommended to ensure safety and efficacy in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is important to assess the potential risks and benefits associated with the use of this drug during pregnancy and lactation. The safety of this medication in pregnant women has not been established, and therefore, caution is advised.

Lactation

Lactating mothers are advised to consult a healthcare professional prior to using this medication. There is limited information available regarding the excretion of this drug in human breast milk and its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring of these patients.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider the potential risks associated with excessive administration of the medication.

It is essential to monitor patients closely for any signs or symptoms that may arise from an overdose. Symptoms may vary depending on the medication's pharmacological profile and the individual patient's response.

In the event of suspected overdosage, immediate medical intervention is recommended. Healthcare providers should initiate supportive care and symptomatic treatment as necessary. It is advisable to consult local poison control centers or relevant medical authorities for guidance on management protocols specific to the medication in question.

Documentation of the incident, including the amount ingested and the time of exposure, is crucial for effective management and follow-up care. Continuous monitoring of the patient's vital signs and clinical status is also recommended to ensure timely intervention if complications arise.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

Postmarketing experience has identified several adverse reactions associated with the use of IGUALTUSS. Reports have included nervousness, dizziness, and sleeplessness. These reactions may occur during treatment. In the event that these symptoms manifest, it is advised to discontinue use and consult a healthcare professional.

Additionally, it is important to note that a cough persisting for more than 7 days, or a cough that returns or occurs alongside fever, rash, or headache lasting for an extended period, could indicate a serious underlying condition.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. It is important to emphasize the potential risks associated with overdose. Patients should be informed that in the event of an accidental overdose, they must seek the advice of a doctor or contact a Poison Control Center immediately. This guidance is crucial for ensuring patient safety and effective management of any adverse situations.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F) and protected from light to prevent degradation. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The medication is administered orally. For adults and children over 12 years of age, the recommended dosage is 1 teaspoonful (5 mL) every 6-8 hours. For children aged 6 to under 12 years, the dosage is 1/2 teaspoonful (2.5 mL) every 6-8 hours. It is advised that parents or guardians consult a doctor before administering the medication to children under 6 years of age.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Igualtuss, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)